Tuesday 16 August 2022 - 04:00
In Business 42 Years - Since 1980
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
S-7979 SP600125, >99%
Synonyms : [1,9-Pyrazoloanthrone] [Anthrapyrazolone] [JNK Inhibitor II] [SAPK Inhibitor II]
- Size
- US $
- €
- £
- ¥
- 50 mg
- 48
- 47
- 39
- 6,400
- In stock
- 100 mg
- 86
- 84
- 71
- 11,400
- In stock
- 300 mg
- 135
- 132
- 111
- 17,900
- In stock
- 500 mg
- 186
- 182
- 153
- 24,700
- In stock
- 1 g
- 334
- 327
- 276
- 44,300
- In stock
- 2 g
- 495
- 485
- 409
- 65,700
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 220.23
- C14H8N2O
- [129-56-6]
Storage: Store at or below -20 ºC. Solubility: Prepare initial stock solutions in DMSO (soluble at 65 mg/mL) for in vitro use; solubility in ethanol or water is low. Disposal: A.
- Novel, potent and selective JNK-1,-2, and -3 inhibitor (Ki = 0.19 µM). SP600125 is an ATP-competitive reversible inhibitor with >20-fold selectivity vs. a range of kinases and enzymes tested. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes IL-2, COX-2, TNF-α, IFN-γ, and blocked the activation and differentiation of primary human CD4 cell cultures. In animal studies, SP600125 inhibited bacterial lipopolysaccharide-induced expression of tumor necrosis factor-α and prevented anti-CD3-induced apoptosis of CD4+ CD8+ thymocytes. Bennett, B.L., et al. "SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase." Proc. Natl. Acad. Sci. USA 98: 13681-13686 (2001).
SP600125 completely inhibited IL-1-induced accumulation of phospho-Jun and initiation of c-Jun transcription in synoviocytes. Han, Z., et al. "c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis." J. Clin. Invest. 108: 73-81 (2001).
Inhibitory activity of SP600125 on various enzymes (adapted from Han, Z., et al.)
Enzyme
IC50 (µM)
Enzyme
IC50 (µM)
JNK1
0.11
Phospholipase A2
> 10
JNK2
0.11
Adenylate cyclase
> 10
JNK3
0.15
Guanylate cyclase
> 10
ERK2
> 30
ATPase (Na/K)
> 10
p38β
> 30
Protein kinase C
> 10
IkB kinase-2
> 30
HIV-1 protease
> 10
Acetylcholine esterase
> 10
Monoamine oxidase
> 10
Cycloxygenase-2
> 10
Tyrosine hydrolase
> 10
5'-lipoxygenase
> 10
Elastase
> 10
PDE I, III, IV, V
> 10
Cathepsin B, G
> 10
iNOS
> 10
EGFR tyrosine kinase
> 10
- SP600125 inhibited JNK, reduced the levels of c-Jun phosphorylation, prevented apoptosis in dopaminergic neurons, and partly reversed the loss of dopamine in MPTP-induced Parkinson's disease in C57BL/6N mice. Wang W., et al. "SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease." Neurosci. Res. 48: 195-202 (2004).
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
